Literature DB >> 22395188

Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee.

Pietro Vajro1, Selvaggia Lenta, Piotr Socha, Anil Dhawan, Patrick McKiernan, Ulrich Baumann, Ozlem Durmaz, Florence Lacaille, Valerie McLin, Valerio Nobili.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children and adolescents in the United States, and most probably also in the rest of the industrialized world.As the prevalence of NAFLD in childhood increases with the worldwide obesity epidemic, there is an urgent need for diagnostic standards that can be commonly used by pediatricians and hepatologists. To this end, we performed a PubMed search of the adult and pediatric literature on NAFLD diagnosis through May 2011 using Topics and/or relevant Authors as search words. According to the present literature, NAFLD is suspected based on the association of fatty liver combined with risk factors (mainly obesity), after the exclusion of other causes of liver disease. The reference but imperfect standard for confirming NAFLD is liver histology. The following surrogate markers are presently used to estimate degree of steatosis and liver fibrosis and risk of progression to end-stage liver disease: imaging by ultrasonography or magnetic resonance imaging, liver function tests, and serum markers of liver fibrosis.NAFLD should be suspected in all of the overweight or obese children and adolescents older than 3 years with increased waist circumference especially if there is a NAFLD history in relatives. The typical presentation, however, is in children ages 10 years and older. The first diagnostic step in these children should be abdominal ultrasound and liver function tests, followed by exclusion of other liver diseases. Overweight/obese children with normal ultrasonographic imaging and normal liver function tests should still be monitored due to the poor sensitivity of these tests at a single assessment.Indications for liver biopsy include the following: to rule out other treatable diseases, in cases of clinically suspected advanced liver disease, before pharmacological/surgical treatment, and as part of a structured intervention protocol or clinical research trial.

Entities:  

Mesh:

Year:  2012        PMID: 22395188     DOI: 10.1097/MPG.0b013e318252a13f

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  141 in total

1.  Edmonton obesity staging system among pediatric patients: a validation and obesogenic risk factor analysis.

Authors:  M G Grammatikopoulou; M Chourdakis; K Gkiouras; P Roumeli; D Poulimeneas; E Apostolidou; I Chountalas; I Tirodimos; O Filippou; S Papadakou-Lagogianni; T Dardavessis
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

2.  Parental perceptions regarding lifestyle interventions for obese children and adolescents with nonalcoholic fatty liver disease.

Authors:  Ingrid Rivera Iñiguez; Jason Yap; Diana R Mager
Journal:  Paediatr Child Health       Date:  2014-05       Impact factor: 2.253

3.  Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design.

Authors:  Bryan Rudolph; Nicole Bjorklund; Nadia Ovchinsky; Debora Kogan-Liberman; Adriana Perez; Mark Liszewski; Terry L Levin; Michelle Ewart; Qiang Liu; Xiaonan Xue; Shankar Viswanathan; Howard D Strickler
Journal:  Contemp Clin Trials       Date:  2018-10-27       Impact factor: 2.226

4.  Accuracy of multiecho magnitude-based MRI (M-MRI) for estimation of hepatic proton density fat fraction (PDFF) in children.

Authors:  Kevin A Zand; Amol Shah; Elhamy Heba; Tanya Wolfson; Gavin Hamilton; Jessica Lam; Joshua Chen; Jonathan C Hooker; Anthony C Gamst; Michael S Middleton; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2015-04-03       Impact factor: 4.813

Review 5.  Pediatric nonalcoholic fatty liver disease: Prevalence, diagnosis, risk factors, and management.

Authors:  Stavra A Xanthakos; Rohit Kohli
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-09-25

6.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

7.  TGF-β-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury.

Authors:  Tsutomu Matsubara; Naoki Tanaka; Misako Sato; Dong Wook Kang; Kristopher W Krausz; Kathleen C Flanders; Kazuo Ikeda; Hans Luecke; Lalage M Wakefield; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2012-10-03       Impact factor: 5.922

8.  Association between nocturnal blood pressure dipping and insulin resistance in children affected by NAFLD.

Authors:  Ugo Giordano; Claudia Della Corte; Giulia Cafiero; Daniela Liccardo; Attilio Turchetta; Kazem Mohammad Hoshemand; Danilo Fintini; Giorgio Bedogni; Maria Chiara Matteucci; Valerio Nobili
Journal:  Eur J Pediatr       Date:  2014-06-17       Impact factor: 3.183

9.  Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups.

Authors:  Stuart A Scott; Benny Liu; Irina Nazarenko; Suparna Martis; Julia Kozlitina; Yao Yang; Charina Ramirez; Yumi Kasai; Tommy Hyatt; Inga Peter; Robert J Desnick
Journal:  Hepatology       Date:  2013-07-29       Impact factor: 17.425

10.  Targeted hepatic sonography during clinic visits for detection of fatty liver in overweight children: a pilot study.

Authors:  Emily R Perito; Patrika M Tsai; Sarah Hawley; Robert H Lustig; Vickie A Feldstein
Journal:  J Ultrasound Med       Date:  2013-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.